Flamingo Therapeutics
Stephane van Rooijen currently serves as the Chief Executive Officer at Flamingo Therapeutics, a company focusing on RNA-targeted therapies for oncology. Previously, Stephane held leadership positions in companies such as Dynacure, Confo Therapeutics, ViroPharma Incorporated, Genzyme, and Arthur D. Little. Stephane holds a Doctor of Medicine (M.D.) degree from KU Leuven, a Master of Business Administration (MBA) degree from Erasmus University Rotterdam, and an MBA-exchange degree from Georgetown University McDonough School of Business. Stephane has a strong background in the medical field and business management.
This person is not in any teams
This person is not in any offices
Flamingo Therapeutics
Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.